Novel Agents for the Acute Conversion of Atrial Fibrillation: Focus on Vernakalant

Publisher： Bentham Science Publishers

E-ISSN： 2212-3962|6|1|1-8

ISSN： 1574-8901

Source： Recent Patents on Cardiovascular Drug Discovery, Vol.6, Iss.1, 2011-01, pp. : 1-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation

By Wettwer Erich   Christ Torsten   Endig Sebastian   Rozmaritsa Nadiia   Matschke Klaus   Lynch Joseph J.   Pourrier Marc   Gibson John K.   Fedida David   Knaut Michael   Ravens Ursula  

Cardiovascular Research, Vol. 98, Iss. 1, 2013-04 ,pp. : 145-154

Oxford University Press

Access to resources Recommend Favorite

Vernakalant (RSD1235) in the management of atrial fibrillation: a review of pharmacological properties, clinical efficacy and safety

By Weeke Peter   Andersson Charlotte   Brendorp Bente   Torp-Pedersen Christian  

Future Cardiology, Vol. 4, Iss. 6, 2008-11 ,pp. : 559-567

Future Medicine

Access to resources Recommend Favorite

Antiarrhythmic Drug Therapy for Atrial Fibrillation: Focus on Atrial Selectivity and Safety

By  

Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents), Vol. 7, Iss. 1, 2009-01 ,pp. : 64-75

Bentham Science Publishers

Access to resources Recommend Favorite

Cryoablation of atrial fibrillation complicated by acute bacterial endocarditis

By Cassagneau Romain  

Journal of Interventional Cardiac Electrophysiology, Vol. 37, Iss. 2, 2013-08 ,pp. : 207-207

Springer Publishing Company

Access to resources Recommend Favorite

Detection of Paroxysmal Atrial Fibrillation in Acute Stroke Patients

By  

Cerebrovascular Diseases, Vol. 30, Iss. 4, 2010-08 ,pp. : 410-417

Karger

Access to resources Recommend Favorite